Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | RAF1 | P04049 | 1/20 | 0.50 |
| ▸ | BRAF | P15056 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL912638 | 0.96 | CYP1A2 (0.55) | CYP1A2CYP2D6MAPTKMT2ARAF1 | |
| SCHEMBL3599828 | 0.84 | CYP1A2 (0.60) | CYP1A2CYP2D6MAPTKMT2ARAF1 | |
| SCHEMBL3600627 | 0.82 | MAPT (0.61) | CYP1A2CYP2D6MAPTKMT2ARAF1 | |
| SCHEMBL27790168 | 0.82 | MAPT (0.57) | CYP1A2CYP2D6MAPTKMT2ARAF1 | |
| SCHEMBL1375024 | 0.82 | KMT2A (0.51) | CYP1A2CYP2D6MAPTKMT2ARAF1 | |
| SCHEMBL2073168 | 0.79 | KMT2A (0.51) | CYP1A2CYP2D6MAPTKMT2ARAF1 | |
| SCHEMBL13141217 | 0.79 | MAPT (0.60) | CYP1A2CYP2D6MAPTKMT2ARAF1 | |
| SCHEMBL18398994 | 0.79 | CYP1A2 (0.60) | CYP1A2CYP2D6MAPTKMT2ARAF1 | |
| SCHEMBL3601715 | 0.79 | MAPT (0.65) | CYP1A2CYP2D6MAPTKMT2ARAF1 | |
| SCHEMBL3598467 | 0.79 | MAPT (0.60) | CYP1A2CYP2D6MAPTKMT2ARAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458687-B1 | PYRIMIDINE COMPOUNDS AS INTERLEUKIN-12 (IL-12) INHIBITORS | SYNTA PHARMACEUTICALS CORP (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110288081-A1 | PYRIMIDINE COMPOUNDS AND USES THEREOF | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-7851466-B2 | Pyrimidine compounds and uses thereof | SYNTA PHARMACEUTICALS CORP. (US) | 2010-12-14 | — | — | US | disclosed |
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-13 | — | — | US | disclosed |
| US-7465725-B2 | Pyrimidine compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2008-12-16 | — | — | US | disclosed |
| US-20080058297-A1 | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-06 | — | — | US | disclosed |
| CN-100349876-C | Pyrimidine compounds | SYNTA PHARMACEUTICALS CORP (US) | 2007-11-21 | — | — | CN | disclosed |
| EP-1827447-A1 | PYRIMIDINE COMPOUNDS AND USES THEREOF | Synta Pharmaceuticals Corporation (US) | 2007-09-05 | — | — | EP | disclosed |
| US-7067514-B2 | Pyrimidine compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-06-27 | — | — | US | disclosed |
| US-20060135518-A1 | Pyrimidine compounds and uses thereof | SYNTA PHARMACEUTICALS CORP. (US) | 2006-06-22 | — | — | US | disclosed |
| EP-1626725-A2 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | Synta Pharmaceuticals Corporation (US) | 2006-02-22 | — | — | EP | disclosed |
| US-20060025409-A1 | e.g. N-{2-[3-(3,4-dimethoxy-phenyl)-propyl]-6-morpholin-4-yl-pyrimidin-4-yl}-N'-(1H-indol-3-ylmethylene)-hydrazine; interleukin-12 antagonist; antiinflammatory, antidiabetic agent; rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis, or insulin-dependent diabetes mellitus | SYNTA PHARMACEUTICALS CORP. (US) | 2006-02-02 | — | — | US | disclosed |
| EP-1458687-A4 | PYRIMIDINE COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2005-03-23 | — | — | EP | disclosed |
| CN-1599726-A | Pyrimidine compounds | SYNTA PHARMACEUTICALS CORP (US) | 2005-03-23 | — | — | CN | disclosed |
| WO-2005000404-A2 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-01-06 | — | — | WO | disclosed |
| EP-1458687-A2 | PYRIMIDINE COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040048873-A1 | Pyrimidine compounds | SYNTA PHARMACEUTICALS CORP., A DELAWARE CORPORATIO | 2004-03-11 | — | — | US | disclosed |
| US-6693097-B2 | Pyrimidine compounds | SYNTA PHARMACEUTICALS CORP. | 2004-02-17 | — | — | US | disclosed |
| US-20030139403-A1 | Pyrimidine compounds | SHIONOGI BIORESEARCH CORP. | 2003-07-24 | — | — | US | disclosed |
| WO-2003047516-A2 | PYRIMIDINE COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025409-A1 | e.g. N-{2-[3-(3,4-dimethoxy-phenyl)-propyl]-6-morpholin-4-yl-pyrimidin-4-yl}-N'-(1H-indol-3-ylmethylene)-hydrazine; interleukin-12 antagonist; antiinflammatory, antidiabetic agent; rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis, or insulin-dependent diabetes mellitus | RORC, NR2C2, OSTC | CYP1A2 1403/4885CYP2D6 1042/4885MAPT 3558/4885 |
| US-20080058297-A1 | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss | BRCA1, VHL, ESR1 | CYP1A2 943/4885CYP2D6 378/4885MAPT 1747/4885 |
| US-20060135518-A1 | Pyrimidine compounds and uses thereof | RORC, IL23R, ORC3 | CYP1A2 562/4885CYP2D6 887/4885MAPT 4251/4885 |
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | BRCA1, VHL, ESR1 | CYP1A2 943/4885CYP2D6 378/4885MAPT 1747/4885 |
| US-20110288081-A1 | PYRIMIDINE COMPOUNDS AND USES THEREOF | RORC, IL23R, ORC3 | CYP1A2 515/4885CYP2D6 760/4885MAPT 4267/4885 |
| US-20030139403-A1 | Pyrimidine compounds | CBR1, CBR3, CCNO | CYP1A2 579/4885CYP2D6 171/4885MAPT 4042/4885 |
| US-20040048873-A1 | Pyrimidine compounds | CBR1, CBR3, CCNO | CYP1A2 684/4885CYP2D6 207/4885MAPT 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.